中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

865 records (took 0.022 seconds)

    INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESIS
    83.
    发明申请
    INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESIS 审中-公开

    公开(公告)号：US20190127454A1

    公开(公告)日：2019-05-02

    申请号：US16091164

    申请日：2017-04-10

    Applicant: Academia Sinica

    Inventor： Ruey-Bing YANG ,  Yuh-Charn LIN

    IPC: C07K16/22 ,  A61P35/00

    Abstract: An isolated anti-SCUBE2 (Signal peptide-complement protein Clr/CIs, Uegf: and Bmp 1 (CUB)-epidermal growth factor (EGF) domain-containing protein 2) antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically hinds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting vascular endothelial growth factor (VEGF)-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.

    HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
    85.
    发明申请
    HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS 审中-公开

    公开(公告)号：US20190099486A1

    公开(公告)日：2019-04-04

    申请号：US16175504

    申请日：2018-10-30

    Applicant: Academia Sinica

    Inventor： Chi-Huey WONG ,  Alice L. YU ,  Kun-Hsien LIN ,  Tai-Na WU

    IPC: A61K39/39 ,  C07H15/18 ,  A61K39/00

    Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

    BENEFICIAL EFFECT OF BIDENS PILOSA ON FAT DECREASE AND MUSCLE INCREASE
    87.
    发明申请
    BENEFICIAL EFFECT OF BIDENS PILOSA ON FAT DECREASE AND MUSCLE INCREASE 审中-公开

    公开(公告)号：US20190000904A1

    公开(公告)日：2019-01-03

    申请号：US16068125

    申请日：2017-01-11

    Applicant: Academia Sinica

    Inventor： Wen-Chin YANG ,  Lee-Tian CHANG ,  Yu-Chuan LIANG

    IPC: A61K36/28 ,  A61K31/7028 ,  A61P3/04 ,  A23L33/105 ,  A23K20/105

    Abstract: A composition comprising a therapeutically effective amount of Bidens pilosa extract, or an active compound isolated from the Bidens pilosa extract for use in treating obesity, reducing body weight or body weight gain, and/or gaining muscle mass or muscle content in a subject in need thereof is disclosed. The composition is useful for reducing fat cell size and/or fat accumulation in the fat cell in a subject in need thereof. The composition may further comprises an animal feed. A polyacetylenic compound for use in treating obesity, gaining muscle mass or muscle content, and/or increasing lean tissue protein content in a subject in need thereof is also disclosed. In one embodiment, the polyacetylenic compound is cytopiloyne.

    ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF
    89.
    发明申请
    ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：US20180362662A1

    公开(公告)日：2018-12-20

    申请号：US16014255

    申请日：2018-06-21

    Applicant: Academia Sinica

    Inventor： Chi-Huey WONG ,  Chung-YI WU

    IPC: C07K16/40 ,  C12P21/00 ,  C07K16/28 ,  C07K16/32 ,  A61K31/517 ,  A61K39/395

    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Patent Agency Ranking